Zoetis Inc Dossier
Qualitative Analysis
Business overview
Zoetis Inc. is the world's leading animal health company, dedicated to advancing animal care through the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostics, and other technologies. Operating across two primary segments—the United States and International—the company serves veterinarians, livestock producers, and pet owners in more than 100 countries. Zoetis supports eight core animal species, including companion animals (dogs, cats, horses) and livestock (cattle, swine, poultry, fish, sheep). Its diverse product portfolio spans seven major categories: parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceuticals, and diagnostics.
Research as of 29 Jul 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Following the achievement of its initial 2021-2025 sustainability targets, Zoetis is sharpening its strategic priorities to focus on three pillars: Communities (advancing opportunities for colleagues and veterinary professionals), Animals (solving sustainability challenges through innovative vaccines and therapies), and Planet (embedding solutions for climate, waste, and nature).
Expected impact: Aims to drive climate action (progressing toward RE100 renewable electricity goal), minimize waste, protect natural ecosystems, and expand access to veterinary care globally.
Effective January 1, 2026, Zoetis eliminated the one-month financial reporting lag for its international subsidiaries, aligning all global operations to a uniform January-December calendar basis.
Expected impact: Improves operational transparency, synchronizes international price increases with the calendar year, and streamlines global financial reporting.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Strengthens Zoetis' leadership in Precision Animal Health by integrating Neogen's global genomics capabilities, fixed-array and sequencing technologies, and software solutions. This acquisition expands predictive insights and individualized care across major livestock and companion animal species.
Financial impact: The acquired business generated approximately $90 million in sales during its fiscal year 2025.
Accelerates diagnostic capabilities by adding around-the-clock access to board-certified veterinary specialists through a cloud-based teleradiology platform. Integrating VitalRADS into Zoetis' Global Diagnostics portfolio enhances reference laboratory services and advances toward an end-to-end Virtual Reference Lab.
Financial impact: Financial terms of the agreement were not disclosed.
Strategic Partnerships
Improves access to care for shelter pets and delivers vital educational resources for pet parents and veterinary healthcare teams nationwide, leveraging Adopt a Pet's network of over 15,000 shelters and rescues.
Terms: Not disclosed
Launches the Dairy Health, Efficiency & Resource Dynamics (Dairy HERD) initiative to advance research in animal health, ensure the economic viability of the U.S. dairy industry, and improve environmental outcomes.
Terms: $1.3 million research collaboration